Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12569718 | 0.88 | TSHR (0.68) | PARP10TSHRKMT2AGAAGLA | |
| SCHEMBL22720413 | 0.85 | TSHR (0.65) | PARP10TSHRKMT2AGAAGLA | |
| SCHEMBL315088 | 0.85 | TSHR (0.72) | PARP10TSHRKMT2AGAAGLA | |
| SCHEMBL6973124 | 0.84 | GAA (0.73) | TSHRKMT2AGAAGLAKDM4E | |
| SCHEMBL12545795 | 0.83 | KMT2A (0.66) | PARP10TSHRKMT2AGAAGLA | |
| SCHEMBL6532498 | 0.82 | PARP10 (0.82) | PARP10TSHRKMT2AGAAGLA | |
| SCHEMBL655882 | 0.81 | KMT2A (0.70) | PARP10TSHRKMT2AGAAGLA | |
| SCHEMBL15651445 | 0.81 | LGMN (0.54) | PARP10TSHRKMT2AGAAGLA | |
| SCHEMBL655166 | 0.81 | LGMN (0.70) | KMT2AKDM4EALDH1A1 | |
| SCHEMBL28972035 | 0.81 | TSHR (0.66) | PARP10TSHRKMT2AGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7060827-B2 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | RIGEL PHARMACEUTICALS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1471915-A4 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | EP | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | MIDCAP FINANCIAL TRUST | 2005-09-22 | — | — | US | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PARP10 1920/4885TSHR 1137/4885KMT2A 921/4885 |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | PARP10 258/4885TSHR 1524/4885KMT2A 2984/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | PARP10 267/4885TSHR 1347/4885KMT2A 1886/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | PARP10 258/4885TSHR 1524/4885KMT2A 2984/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PARP10 258/4885TSHR 1524/4885KMT2A 2984/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PARP10 258/4885TSHR 1524/4885KMT2A 2984/4885 |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PARP10 258/4885TSHR 1524/4885KMT2A 2984/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PARP10 258/4885TSHR 1524/4885KMT2A 2984/4885 |
| US-20050209230-A1 | 2-leaving group-4-(substituted amino)-5-fluoropyrimidines such as 2-chloro-N4-(2-hydroxyphenyl)-5-fluoro-4-pyrimidineamine; chemical intermediates to compounds that inhibit the immunoglobulin (Ig) IgE and/or IgG receptor signaling cascades | FCER2, FCGR1A, FCGR2A | PARP10 811/4885TSHR 1960/4885KMT2A 2086/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | PARP10 952/4885TSHR 1104/4885KMT2A 4638/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PARP10 258/4885TSHR 1524/4885KMT2A 2984/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | PARP10 258/4885TSHR 1524/4885KMT2A 2984/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PARP10 258/4885TSHR 1524/4885KMT2A 2984/4885 |
| US-20070293524-A1 | Salts, hydrates, solvatesand/or N-oxides; inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; Syk kinase inhibitors; inhibiting an Fc receptor signal transduction cascade | SYK, FCER2, FCGR1A | PARP10 1976/4885TSHR 1386/4885KMT2A 3199/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PARP10 1910/4885TSHR 1024/4885KMT2A 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.